The relationship between Helicobacter pylori-related microbiota dysbiosis and gastrointestinal tract pathologies by Kountouras, Jannis et al.








The relationship between Helicobacter pylori-related microbiota dysbiosis
and gastrointestinal tract pathologies
Kountouras, Jannis ; Doulberis, Michael ; Papaefthymiou, Apostolis ; Polyzos, Stergios A ; Touloumtzi,
Maria ; Vardaka, Elisabeth ; Kapetanakis, Nikolaos ; Liatsos, Christos ; Gavalas, Emmanouel ;
Anastasiadis, Sotiris ; Tzivras, Dimitri ; Katsinelos, Panagiotis
DOI: https://doi.org/10.1080/00365521.2019.1619826




Kountouras, Jannis; Doulberis, Michael; Papaefthymiou, Apostolis; Polyzos, Stergios A; Touloumtzi,
Maria; Vardaka, Elisabeth; Kapetanakis, Nikolaos; Liatsos, Christos; Gavalas, Emmanouel; Anastasiadis,
Sotiris; Tzivras, Dimitri; Katsinelos, Panagiotis (2019). The relationship between Helicobacter pylori-




The relationship between Helicobacter pylori–related 
microbiota dysbiosis and gastrointestinal tract pathologies  
 
Jannis Kountouras, MD, PhD1, Michael Doulberis, MD,DVM, PhD1,2, 
Apostolis Papaefthimiou, MD1,3,  Stergios A. Polyzos, MD, Msc, PhD1,4, 
Maria Touloumtzi, MD1, Elisabeth Vardaka, PhD1, Nikolaos Kapetanakis, 
MD, PhD1, Christos Liatsos, MD, PhD1,3, Emmanouel Gavalas, MD, PhD1, 
Sotiris Anastasiadis, MD1, Dimitri Tzivras, MD,PhD5, Panagiotis 
Katsinelos, MD, PhD1. 
 
1Department of Gastroenterology, Second Medical Clinic, Aristotle University of 
Thessaloniki, Ippokration Hospital, Thessaloniki, Greece 
2Department of Gastroenterology and Hepatology, University of Zurich, Zurich 8091, 
Switzerland 
3Department of Gastroenterology, 401 General Military Hospital of Athens, Athens 
11525, Greece 
4First Department of Pharmacology, Medical School, Aristotle University of 
Thessaloniki, Thessaloniki 54642, Macedonia, Greece 
 
5St. Elisabeth-Hospital Herten GmbH, 45699 Herten, Germany 
 
 
Key words: Helicobacter pylori; gastric microbiota; dysbiosis; gastric cancer; 
esophageal cancer  
Conflict of Interest: None declared 
 
Please address correspondence to: 
 2 
Jannis Kountouras, MD, PhD 
Professor of Medicine 
8 Fanariou St, Byzantio 
551 33, Thessaloniki, Macedonia, 
Greece 
Tel: +30-2310-892238, Fax: +30-2310-992794 
E-mail: jannis@auth.gr, ancorarus2010@gmail.com 
 3 
To the Editor, 
In their review, Zhang et al. [1], concluded that gastrointestinal microbiota (GI-
M) plays an essential role in the development and progression of gastric pathologies; 
they considered a potential impact of Helicobacter pylori infection (Hp-I) on gastric 
microbiota (GM) composition in gastric cancer (GC) pathophysiology, though it 
remains to be elucidated. 
In this regard, apart form the mentioned gastric microbiota influenced by Hp 
colonization, the authors did not take into consideration specific pathogens including 
species frorm Campylobacter genus that appear to be involved in gastric 
carcinogenesis. Hp abundance is positively correlated with the presence 
of Campylobacter which is the most well-connected and influential bacterium observed 
in Hp-related atrophic gastritis patients and could be an substantial contributor to 
gastric carcinogenesis [2,3]. 
In this concern, it has been proposed that chronic Hp-I induces atrophic gastritis 
accompanying by decreased acid secretion and acid reflux, thereby reducing the risk 
of gastroesophageal reflux disease (GERD) and its complications Barrett’s esophagus 
(BE) and esophageal adenocarcinoma (EAC) [4]. However, this conventional 
consideration might represent a double‑ edged sword one view. Regarding the 
opposed view, hypochlorhdria induced by Hp-related atrophic gastritis, results in 
dysbiosis of GI-M, which, beyond GC, could also contribute to BE-EAC sequence [3,5]. 
Data on BE biofilm show high level of atypical nitrate reducing Campylobacter species 
in BE, compared with non-BE specimens [6] and these species might contribute to 
development, exacerbation and/or BE progression to EAC through chronic 
inflammation [5]. Therefore, Campylobacter species and other pathgens-related 
dysbiosis associated with Hp-induced atrophic gastritis might be etiological agents of 
the chronic esophageal inflammation leading to EAC development [5,7] and thus 
further investigation is needed.  
 The authors considered molecular mechanisms involved in Hp-I related gastric 
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cancinogenesis [1]. Likewise, concerning the role of molecular events involved in Hp-
I-related GERD- BE-EAC sequence, we recently summarized [8] comparable Hp-
related mechanisms such as the following: Hp induction of upper and lower 
gastrointestinal tract (GIT) oncogenic gastrin, which stimulates proliferation via Janus 
Kinase (JAK) 2 and Akt-dependent nuclear factor-kappa B (NF-κB) activation in 
Barrett's EAC cells, displays a anti-apoptotic effect through Bcl-2 protein and survivin 
upregulations, and induces the mitogenic and oncogenic cyclooxygenase (COX)-2 
expression. Hp activates the mentioned NF-κB, a transcription regulator of 
inflammatory genes, including COX-2 that regulates gastrointestinal neoplasm cell 
growth and proliferation. Prostaglandins (PGs) derived from upregulated COX-2 
contribute to BE cancer progression, by perpetuating chronic inflammation and the 
mitogenic and antiapoptotic effects of PGs are mediated through activation of several 
aforementioned signaling pathways including NF-κB, Src, JAK2/STAT3, ERK, MAPK 
and PI3K/Akt kinases. Moreover, Hp-I could induce specific molecular changes 
(genetic instability, E-cadherin methylation, monoclonal antibody Das-1) linked with BE 
pathophysiology, and promotes Ki-67 expression predicting malignant progression in 
BE. Finally, Hp-related metabolic syndrome (MetS) disorders that associated with GI-
M dysbiosis appear to be involved in gastric and esophageal carcinogenesis [9,10]. 
Again, we recently reviewed several Hp-related MetS mechanisms involved in upper 
and lower GIT oncogenic processes [9]. 
Therefore, Hp eradication and manipulation of its related GI-M dysbiosis might inhibit 
the aforementioned GIT oncogenic processes, and thus further studies are necessary. 
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